Literature DB >> 32414946

Exploiting the Full Potential of β-Amyloid and Tau PET Imaging for Drug Efficacy Testing.

Henryk Barthel1, John Seibyl2, Adriaan A Lammertsma3, Victor L Villemagne4,5, Osama Sabri6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32414946      PMCID： PMC7413238          DOI： 10.2967/jnumed.119.228346

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  6 in total

1.  Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Authors:  Jeff Sevigny; Ping Chiao; Thierry Bussière; Paul H Weinreb; Leslie Williams; Marcel Maier; Robert Dunstan; Stephen Salloway; Tianle Chen; Yan Ling; John O'Gorman; Fang Qian; Mahin Arastu; Mingwei Li; Sowmya Chollate; Melanie S Brennan; Omar Quintero-Monzon; Robert H Scannevin; H Moore Arnold; Thomas Engber; Kenneth Rhodes; James Ferrero; Yaming Hang; Alvydas Mikulskis; Jan Grimm; Christoph Hock; Roger M Nitsch; Alfred Sandrock
Journal:  Nature       Date:  2017-06-21       Impact factor: 49.962

Review 2.  Forward to the Past: The Case for Quantitative PET Imaging.

Authors:  Adriaan A Lammertsma
Journal:  J Nucl Med       Date:  2017-05-18       Impact factor: 10.057

3.  Validation of Noninvasive Tracer Kinetic Analysis of 18F-Florbetaben PET Using a Dual-Time-Window Acquisition Protocol.

Authors:  Santiago Bullich; Henryk Barthel; Norman Koglin; Georg A Becker; Susan De Santi; Aleksandar Jovalekic; Andrew W Stephens; Osama Sabri
Journal:  J Nucl Med       Date:  2017-11-24       Impact factor: 10.057

Review 4.  The role of positron emission tomography imaging in understanding Alzheimer's disease.

Authors:  Henryk Barthel; John Seibyl; Osama Sabri
Journal:  Expert Rev Neurother       Date:  2015-03-09       Impact factor: 4.618

5.  Longitudinal amyloid imaging using 11C-PiB: methodologic considerations.

Authors:  Bart N M van Berckel; Rik Ossenkoppele; Nelleke Tolboom; Maqsood Yaqub; Jessica C Foster-Dingley; Albert D Windhorst; Philip Scheltens; Adriaan A Lammertsma; Ronald Boellaard
Journal:  J Nucl Med       Date:  2013-08-12       Impact factor: 10.057

6.  Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies.

Authors:  Fiona Heeman; Maqsood Yaqub; Isadora Lopes Alves; Kerstin Heurling; Johannes Berkhof; Juan Domingo Gispert; Santiago Bullich; Christopher Foley; Adriaan A Lammertsma
Journal:  EJNMMI Res       Date:  2019-03-27       Impact factor: 3.138
  6 in total
  2 in total

1.  The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community.

Authors:  Valentina Garibotto; Nathalie L Albert; Henryk Barthel; Bart van Berckel; Ronald Boellaard; Matthias Brendel; Diego Cecchin; Ozgul Ekmekcioglu; Elsmarieke van de Giessen; Eric Guedj; Adriaan A Lammerstma; Franck Semah; Tatjana Traub-Weidinger; Donatienne Van Weehaeghe; Silvia Morbelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-17       Impact factor: 9.236

Review 2.  Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Authors:  Gérard N Bischof; Alessandra Dodich; Marina Boccardi; Thilo van Eimeren; Cristina Festari; Henryk Barthel; Oskar Hansson; Agneta Nordberg; Rik Ossenkoppele; Osama Sabri; B Frisoni G Giovanni; Valentina Garibotto; Alexander Drzezga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-16       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.